Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
One hundred subjects will receive study drug or matching placebo over 12 weeks of consecutive dosing. Following a short Run‐in Period, eligible subjects will enter the Primary Assessment Period and receive twice‐daily dosing of study drug or placebo for 12 weeks. Following 12 weeks of treatment, subjects will enter a 12‐week Eosinophil Recovery Period. The primary endpoint for the study is the change in blood absolute eosinophil count from Baseline to Week 12.
Epistemonikos ID: 0f1c3c8001a3bfbc1c39ea3406fbc96799449aaf
First added on: Jul 25, 2023